Canosa, Antonio http://orcid.org/0000-0001-5876-4079
Martino, Alessio
Giuliani, Alessandro
Moglia, Cristina
Vasta, Rosario
Grassano, Maurizio
Palumbo, Francesca
Cabras, Sara
Di Pede, Francesca
De Mattei, Filippo
Matteoni, Enrico
Polverari, Giulia
Manera, Umberto
Calvo, Andrea
Pagani, Marco
Chiò, Adriano
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017 (grant 2017SNW5MB), The Joint Programme - Neurodegenerative Disease Research (Strength, ALS-Care, Brain Mend projects), Department of Excellence grant)
Fondation Thierry Latran (INSPIRED Project)
Ministero della Salute (RF-2016-02362405)
European Commission (Health Seventh Framework Programme (FP7/2007-2013, grant agreement 259867))
Università degli Studi di Torino
Article History
Received: 19 August 2022
Revised: 19 October 2022
Accepted: 20 October 2022
First Online: 2 November 2022
Declarations
:
: Antonio Canosa, Alessio Martino, Alessandro Giuliani, Cristina Moglia, Rosario Vasta, Maurizio Grassano, Francesca Palumbo, Sara Cabras, Francesca Di Pede, Filippo De Mattei, Enrico Matteoni, Giulia Polverari, Umberto Manera, and Marco Pagani report no disclosures relevant to the manuscript. Andrea Calvo has received a research grant from Cytokinetics. Adriano Chiò serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Cytokinetics, Denali Therapeutics, Amylyx, and AveXis.
: The study has been approved by the ethical committee of the ‘Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino’ (protocol number 0011669) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was obtained from all individual participants included in the study.